Christoph C. Zielinski

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 187 publications

11th Immunotherapy of Cancer conference (ITOC): A meeting report.

11th Immunotherapy of Cancer conference (ITOC): A meeting report.

Journal: Human vaccines & immunotherapeutics

Published: July 18, 2025

Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.

Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.

Journal: JCO precision oncology

Published: July 09, 2025

Multidisciplinary expert consensus on diagnosis and treatment of multiple lung cancers.

Multidisciplinary expert consensus on diagnosis and treatment of multiple lung cancers.

Journal: Med (New York, N.Y.)

Published: December 28, 2024

Breakthrough Infections in SARS-CoV-2-Vaccinated Multiple Myeloma Patients Improve Cross-Protection against Omicron Variants.

Breakthrough Infections in SARS-CoV-2-Vaccinated Multiple Myeloma Patients Improve Cross-Protection against Omicron Variants.

Journal: Vaccines

Published: March 27, 2024

Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON).

Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON).

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 14, 2024

Preclinical and Clinical Observations Implying Combination Therapy to Enhance the Efficacy of the Her-2/neu B-Cell Peptide-Based Vaccine HER-Vaxx and to Prevent Immune Evasion.

Preclinical and Clinical Observations Implying Combination Therapy to Enhance the Efficacy of the Her-2/neu B-Cell Peptide-Based Vaccine HER-Vaxx and to Prevent Immune Evasion.

Journal: International journal of molecular sciences

Published: November 20, 2023

Cetuximab every 2 weeks versus standard weekly dosing administration schedule.

Cetuximab every 2 weeks versus standard weekly dosing administration schedule.

Journal: Future oncology (London, England)

Published: October 18, 2023

Interactions of EGFR/PTEN/mTOR-Pathway Activation and Estrogen Receptor Expression in Cervical Cancer.

Interactions of EGFR/PTEN/mTOR-Pathway Activation and Estrogen Receptor Expression in Cervical Cancer.

Journal: Journal of personalized medicine

Published: July 03, 2023

"What's measured gets done": a call for a European semester for cancer to improve cancer outcomes in Central and Southeastern Europe.

"What's measured gets done": a call for a European semester for cancer to improve cancer outcomes in Central and Southeastern Europe.

Journal: Archives of public health = Archives belges de sante publique

Published: April 21, 2023

Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.

Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 28, 2023

9th Immunotherapy of Cancer conference (ITOC): A meeting report.

9th Immunotherapy of Cancer conference (ITOC): A meeting report.

Journal: Human vaccines & immunotherapeutics

Published: December 28, 2022

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.

Journal: Nature medicine

Published: December 13, 2022

Showing 1-12 of 187

Last Updated: 09/26/2026